Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Yoshio Okano

Showing results (31-40 of 40) with videos related to

Pageof 4
Sort By:
You have reached the last page of results.This site can display upto 40 results.
Thoracic Cancer|September 5, 2023
Pretreatment eosinophil counts as a predictive biomarker in non-small cell lung cancer patients treated with immune checkpoint inhibitorsEiji Takeuchi, Kensuke Kondo, Yoshio Okano, et al.
Thoracic Cancer|December 17, 2024
Pathological Complete Response to a Single Dose of Pembrolizumab-Based Chemoimmunotherapy for Squamous Cell Carcinoma of the Lung: A Case ReportYugo Matsumura, Seiya Ichihara, Kaori Nii, et al.
Thoracic Cancer|December 13, 2023
An increased relative eosinophil count as a predictive dynamic biomarker in non-small cell lung cancer patients treated with immune checkpoint inhibitorsEiji Takeuchi, Hirokazu Ogino, Kensuke Kondo, et al.
Journal of Cancer Research and Clinical Oncology|July 24, 2022
Early mortality factors in immune checkpoint inhibitor monotherapy for advanced or metastatic non-small cell lung cancerEiji Takeuchi, Kensuke Kondo, Yoshio Okano, et al.
Journal of Geriatric Oncology|August 25, 2022
Predicting systemic therapy toxicity in older adult patients with advanced non-small cell lung cancer: A prospective multicenter study of National Hospital Organization in JapanMasaki Kanazu, Mototsugu Shimokawa, Ryusei Saito, et al.
Thoracic Cancer|April 19, 2023
Clinical benefit of platinum doublet combination therapy in older adults with advanced non-small cell lung cancer: A prospective multicenter study by the National Hospital Organization in JapanMototsugu Shimokawa, Masaki Kanazu, Ryusei Saito, et al.
Anticancer Research|January 2, 2016
Carboplatin plus Weekly Paclitaxel with Bevacizumab for First-line Treatment of Non-small Cell Lung CancerTetsuya Kubota, Yoshio Okano, Mizu Sakai, et al.
Oncology Letters|August 7, 2012
A multi-institutional phase II study of combination chemotherapy with S-1 plus cisplatin in patients with advanced non-small cell lung cancerHideki Tomimoto, Masaki Hanibuchi, Fumitaka Ogushi, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 21, 2014
Randomized phase III trial of erlotinib versus docetaxel as second- or third-line therapy in patients with advanced non-small-cell lung cancer: Docetaxel and Erlotinib Lung Cancer Trial (DELTA)Tomoya Kawaguchi, Masahiko Ando, Kazuhiro Asami, et al.
International Journal of Clinical Oncology|July 15, 2024
Granulocyte colony-stimulating factor has the potential to attenuate the therapeutic efficacy of chemo-immunotherapy for extensive-stage small-cell lung cancerYuki Tsukazaki, Hirokazu Ogino, Yoshio Okano, et al.
Pageof 4

Showing results (31-40 of 40) with videos related to

Sort By:
Pageof 4
You have reached the last page of results.This site can display upto 40 results.
Thoracic Cancer|September 5, 2023
Pretreatment eosinophil counts as a predictive biomarker in non-small cell lung cancer patients treated with immune checkpoint inhibitorsEiji Takeuchi, Kensuke Kondo, Yoshio Okano, et al.
Thoracic Cancer|December 17, 2024
Pathological Complete Response to a Single Dose of Pembrolizumab-Based Chemoimmunotherapy for Squamous Cell Carcinoma of the Lung: A Case ReportYugo Matsumura, Seiya Ichihara, Kaori Nii, et al.
Thoracic Cancer|December 13, 2023
An increased relative eosinophil count as a predictive dynamic biomarker in non-small cell lung cancer patients treated with immune checkpoint inhibitorsEiji Takeuchi, Hirokazu Ogino, Kensuke Kondo, et al.
Journal of Cancer Research and Clinical Oncology|July 24, 2022
Early mortality factors in immune checkpoint inhibitor monotherapy for advanced or metastatic non-small cell lung cancerEiji Takeuchi, Kensuke Kondo, Yoshio Okano, et al.
Journal of Geriatric Oncology|August 25, 2022
Predicting systemic therapy toxicity in older adult patients with advanced non-small cell lung cancer: A prospective multicenter study of National Hospital Organization in JapanMasaki Kanazu, Mototsugu Shimokawa, Ryusei Saito, et al.
Thoracic Cancer|April 19, 2023
Clinical benefit of platinum doublet combination therapy in older adults with advanced non-small cell lung cancer: A prospective multicenter study by the National Hospital Organization in JapanMototsugu Shimokawa, Masaki Kanazu, Ryusei Saito, et al.
Anticancer Research|January 2, 2016
Carboplatin plus Weekly Paclitaxel with Bevacizumab for First-line Treatment of Non-small Cell Lung CancerTetsuya Kubota, Yoshio Okano, Mizu Sakai, et al.
Oncology Letters|August 7, 2012
A multi-institutional phase II study of combination chemotherapy with S-1 plus cisplatin in patients with advanced non-small cell lung cancerHideki Tomimoto, Masaki Hanibuchi, Fumitaka Ogushi, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 21, 2014
Randomized phase III trial of erlotinib versus docetaxel as second- or third-line therapy in patients with advanced non-small-cell lung cancer: Docetaxel and Erlotinib Lung Cancer Trial (DELTA)Tomoya Kawaguchi, Masahiko Ando, Kazuhiro Asami, et al.
International Journal of Clinical Oncology|July 15, 2024
Granulocyte colony-stimulating factor has the potential to attenuate the therapeutic efficacy of chemo-immunotherapy for extensive-stage small-cell lung cancerYuki Tsukazaki, Hirokazu Ogino, Yoshio Okano, et al.
Pageof 4